Delivery Order SPE2DR25D1103-SPE2DR26FD835
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a ceiling value of $10,496.42. This firm fixed-price delivery order represents a non-competitive, non-set-aside award and is scheduled for completion by October 24, 2025. The contract will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a contract ceiling value of $9,461.61. This firm fixed-price delivery order, which is not set-aside, is expected to be completed by November 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Otezla 30 mg tablets (60-count units) valued at $16,575.87 under a firm fixed-price arrangement. The contract is non-competitive with no set-aside designation and requires completion by September 11, 2025. This delivery order is issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive $999,999,999...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of Otezla 30 mg tablets (60-count) valued at $10,291.31 under a firm fixed-price contract. This competitive award, which carries no set-aside designation, represents a direct purchase order for this pharmaceutical product to support federal medical supply needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a delivery order valued at $26,675.43 to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Otezla 30 mg tablets (60-count packaging). The contract represents a firm fixed price delivery order with an ultimate completion date of December 2, 2025, and was competitively awarded without any set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for supply of Otezla 30 mg tablets in quantities of 60 units. This firm fixed-price delivery order, valued at $48,488.62 with an ultimate completion date of July 30, 2025, represents a non-set-aside competitive award. The product will be delivered to AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 31, 2025, for the supply of Otezla 30 mg tablets (60-count packages) valued at $40,595.88. This firm fixed-price, non-set-aside contract is scheduled for completion by November 3, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $5,976.54 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 12, 2025, with an ultimate completion date of August 13, 2025. This contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) with a ceiling value of $50,159.07. This is a firm fixed-price delivery order with no set-aside designation, issued on November 10, 2025, with an ultimate completion date of November 12, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order valued at $16,991.63 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units). This competitively awarded, non-set-aside contract utilizes firm fixed pricing and carries an ultimate completion date of September 15, 2025. The delivery order was issued on September 12, 2025, with performance to take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is executed under...
- SPE2DR25D1103Indefinite Delivery Contract
- SPE2DR25D1103-SPE2DR26FD835Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 10, 2025, for supply of Otezla 30 mg tablets (60-count units) with a ceiling value of $16,775.89. This firm fixed-price delivery order, with an ultimate completion date of November 12, 2025, represents a non-competitive set-aside award to the pharmaceutical distributor. The contract is performed at AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a prime vendor under this comprehensive global pharmaceutical support vehicle, AmerisourceBergen supplies a broad range of pharmaceutical products and medical supplies to support military healthcare programs and Defense Health Agency customers worldwide. The delivery order for Otezla—a brand-name pharmaceutical used primarily to treat psoriatic arthritis and other inflammatory conditions—exemplifies the company's role in fulfilling specialized pharmaceutical procurement needs within the Department of Defense medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.8k | 11/10/25 |